LifeMD (NASDAQ:LFMD) Issues Earnings Results

LifeMD (NASDAQ:LFMD) released its earnings results on Wednesday. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06), Zacks reports. LifeMD had a negative return on equity of 176.40% and a net margin of 2.37%.The company had revenue of $50.16 million during the quarter, compared to analysts’ expectations of $48.84 million.

Here are the key takeaways from LifeMD’s conference call:

• Q1 revenue of $50.2 million beat guidance and the company added >42,000 net telehealth subscribers (its largest quarter), ending with >365,000 subscribers; management reaffirmed 2026 guidance of $220–$230M and a path to >$250M revenue and >$25M adjusted EBITDA run‑rate by Q4.
• Rapid traction in core care areas — weight management sign‑ups rose ~120% sequentially to nearly 100,000 patients with improved CACs, and the women’s health program grew >7x from the Q4 base with on‑therapy retention north of 80%.
• Gross margin expanded ~420 bps to 88% driven by in‑house pharmacy and lower fulfillment costs, but Q1 showed a GAAP net loss of $9.6M and an adjusted EBITDA loss of ~$4.5M due to front‑loaded marketing that management expects will normalize and improve profitability in H2.
• Scaling levers — aggressive AI deployment to increase provider capacity, a 22,500 sq ft, 50‑state pharmacy processing ~20,000 prescriptions/month, and insurance coverage rolling from ~112M toward ~230M covered lives (including a Medicare GLP‑1 Bridge launching July 1) — are positioned to support retention and margin expansion.
• Strategic and execution risks remain as the product mix shifts from compounded to branded GLP‑1s (pressuring YoY revenue and producing variable unit economics), details on Novo/Lilly partnerships are limited under NDA, and Q2 guide is modest at $47–$50M revenue and adjusted EBITDA of -$2M to $1M.

LifeMD Price Performance

Shares of LifeMD stock traded up $0.24 on Friday, hitting $4.73. 520,658 shares of the company’s stock traded hands, compared to its average volume of 1,177,336. The firm’s 50-day moving average price is $3.87 and its two-hundred day moving average price is $3.93. The stock has a market capitalization of $224.91 million, a PE ratio of 94.52 and a beta of 2.03. LifeMD has a one year low of $2.56 and a one year high of $15.84.

Institutional Trading of LifeMD

Institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC grew its holdings in LifeMD by 13.6% during the fourth quarter. Barclays PLC now owns 61,028 shares of the company’s stock valued at $208,000 after purchasing an additional 7,300 shares during the period. Squarepoint Ops LLC acquired a new position in LifeMD during the fourth quarter valued at approximately $204,000. Jump Financial LLC grew its holdings in LifeMD by 26.4% during the fourth quarter. Jump Financial LLC now owns 59,925 shares of the company’s stock valued at $204,000 after purchasing an additional 12,525 shares during the period. Aristides Capital LLC acquired a new position in LifeMD during the fourth quarter valued at approximately $203,000. Finally, Verition Fund Management LLC grew its holdings in LifeMD by 62.0% during the fourth quarter. Verition Fund Management LLC now owns 54,893 shares of the company’s stock valued at $187,000 after purchasing an additional 21,004 shares during the period. Institutional investors own 35.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on LFMD shares. Mizuho upgraded shares of LifeMD from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $6.00 to $8.00 in a research note on Monday, March 16th. BTIG Research restated a “buy” rating and set a $10.00 price target on shares of LifeMD in a research note on Monday. Wall Street Zen upgraded shares of LifeMD from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of LifeMD in a research note on Tuesday, March 10th. Finally, HC Wainwright raised their target price on shares of LifeMD from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, LifeMD currently has a consensus rating of “Moderate Buy” and an average target price of $9.14.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.